Co-Diagnostics, Inc. (CODX) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Co-Diagnostics reported revenue of $622,489, down 84.1% from $3.9M the year before. Net income was -$46.9M (a -7533.6% net margin), or -$35.25 per diluted share. Gross margin was 64.3% and operating margin was -8058.8%. Operating activities generated -$29.1M of cash, leaving -$29.8M of free cash flow. At fiscal year end, Co-Diagnostics held $24.7M in total assets against $4.1M in total liabilities, including $11.9M of cash and equivalents.
Open the full interactive Co-Diagnostics financials → Quarterly statements, key ratios, valuation history and price charts.
Co-Diagnostics Key Stats
| Share Price | $1.07 |
|---|---|
| Market Cap | $4.6M |
| Revenue YoY Growth | -84.1% |
| 52-Week Range | $0.94 – $37.80 |
| Shares Outstanding | 4.3 million (basic, 2026 Q2) |
Co-Diagnostics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $74.6M | $97.9M | $34.2M | $6.8M | $3.9M | $622,489 |
| Gross Profit | $58.0M | $86.3M | $28.7M | $2.6M | $2.9M | $400,112 |
| Operating Income | $41.7M | $46.1M | -$27.0M | -$42.7M | -$40.1M | -$50.2M |
| Pre-Tax Income | $42.6M | $45.6M | -$18.8M | -$38.1M | -$37.6M | -$48.5M |
| Income Tax | $90,536 | $9.0M | -$4.6M | -$2.8M | $57,368 | -$1.6M |
| Net Income | $42.5M | $36.7M | -$14.2M | -$35.3M | -$37.6M | -$46.9M |
| Diluted EPS | $45.60 | $36.90 | -$13.50 | -$36.00 | -$37.20 | -$35.25 |
Co-Diagnostics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $145,380 | $263,922 | $145,954 | $166,131 |
| Net Income | -$5.9M | -$25.7M | -$9.1M | -$6.3M |
| Diluted EPS | -$4.80 | -$19.35 | -$4.06 | -$1.46 |
Co-Diagnostics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $43.0M | $88.6M | $23.0M | $14.9M | $2.9M | $11.9M |
| Current Assets | $68.4M | $115.1M | $92.7M | $62.1M | $32.3M | $13.7M |
| Total Assets | $71.2M | $160.0M | $123.1M | $95.3M | $64.0M | $24.7M |
| Current Liabilities | $4.5M | $12.6M | $3.9M | $5.7M | $7.3M | $3.5M |
| Total Liabilities | $4.5M | $25.6M | $8.6M | $9.3M | $9.7M | $4.1M |
| Shareholders' Equity | $66.7M | $134.5M | $114.5M | $86.0M | $54.3M | $20.6M |
Co-Diagnostics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $28.2M | $41.1M | $6.6M | -$22.1M | -$29.2M | -$29.1M |
| Cash From Investing | -$5.8M | $4.1M | -$58.2M | $15.4M | $17.1M | $26.3M |
| Cash From Financing | $19.7M | $450,398 | -$14.0M | -$1.4M | $103,914 | $11.8M |
| Free Cash Flow | $27.4M | $40.4M | $5.1M | -$23.4M | -$29.9M | -$29.8M |
Figures from Co-Diagnostics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Co-Diagnostics financials page for every line item.
Co-Diagnostics Company Profile
| Ticker | CODX |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Salt Lake City, Utah |
| Incorporated in | Utah |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001692415 |
Frequently Asked Questions
What was Co-Diagnostics' revenue in fiscal 2025?
Co-Diagnostics (CODX) reported revenue of $622,489 for fiscal 2025.
What is Co-Diagnostics' annual revenue history?
Co-Diagnostics' annual revenue by fiscal year: 2020: $74.6M; 2021: $97.9M; 2022: $34.2M; 2023: $6.8M; 2024: $3.9M; 2025: $622,489.
What was Co-Diagnostics' net income in fiscal 2025?
Co-Diagnostics reported net income of -$46.9M for fiscal 2025.
What was Co-Diagnostics' earnings per share (EPS) in fiscal 2025?
Co-Diagnostics' diluted EPS was -$35.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Co-Diagnostics generate in fiscal 2025?
Co-Diagnostics generated -$29.8M of free cash flow in fiscal 2025.
What was Co-Diagnostics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Co-Diagnostics reported revenue of $166,131.
How many shares of Co-Diagnostics are outstanding?
Co-Diagnostics reported a weighted average of 4.3 million basic shares outstanding in 2026 Q2.
What is Co-Diagnostics' market cap?
Based on its latest closing price, Co-Diagnostics (CODX) has a market capitalization of about $4.6M.
When does Co-Diagnostics' fiscal year end?
Co-Diagnostics' fiscal year end, as registered with the SEC, is December 31.
Where is Co-Diagnostics headquartered?
Co-Diagnostics lists its business address in Salt Lake City, Utah in its SEC filings.
Co-Diagnostics Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →